Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.51 |
| ▸ | BCR | P11274 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 5/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2355648 | 0.87 | ABL1 (0.60) | ABL1ABCB1BCRSYKPTPN1 | |
| SCHEMBL2090898 | 0.82 | MEN1 (0.49) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL20550260 | 0.78 | PTPRC (0.54) | ABL1ABCB1BCRPTPRCPTPN1 | |
| SCHEMBL6163752 | 0.77 | KDM4E (0.60) | ABL1ABCB1BCRSYKHDAC4 | |
| SCHEMBL1704521 | 0.77 | ABL1 (0.62) | ABL1ABCB1BCRSYKPTPRC | |
| SCHEMBL29899709 | 0.75 | CA12 (0.60) | ABL1ABCB1BCRSYKHDAC4 | |
| SCHEMBL17012446 | 0.75 | — | — | |
| SCHEMBL8501330 | 0.75 | L3MBTL1 (0.60) | ABL1ABCB1BCRSYKHDAC4 | |
| SCHEMBL967992 | 0.75 | BRD4 (0.49) | ABL1ABCB1BCRHDAC4HDAC8 | |
| SCHEMBL2091091 | 0.75 | ALDH1A1 (0.50) | SYKHDAC4HDAC2HDAC8BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846898-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotide having reduced internucleotide charge | Lieure Cornu LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | LIEVRE CORNU LLC (US) | 2010-12-09 | — | — | US | disclosed |
| US-7745591-B2 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | Lievre Cornu, LLC (US) | 2010-06-29 | — | — | US | disclosed |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | LIEVRE CORNU LLC (US) | 2006-12-28 | — | — | US | disclosed |
| US-7067641-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge | LIEVRE CORNU LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040116687-A1 | oligonucleotides having reduced internucleotide charge and enhanced nuclease resistance | AGILENT TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6693187-B1 | ENHANCING NUCLEASE RESISTANCE | LIEVRE CORNU LLC | 2004-02-17 | — | — | US | disclosed |
| US-5750666-A | FOR SYNTHESIZING NEW MONONUCLEOTIDES AND POLYNUCLEOTIDES HAVING PHOSPHOROTHIOATE AND PHOSPHORODITHIOATE INTERNUCLEOTIDE LINKAGES | COMPETITVE TECHNOLOGIES, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5684148-A | NUCLEOSIDES AND POLYNUCLEOTIDES AS FLUORESCENT AGENTS FOR MEDICAL DIAGNOSIS | COMPETITIVE TECHNOLOGIES, INC. (US) | 1997-11-04 | — | — | US | disclosed |
| US-5602244-A | DINUCLEOSIDE PRECURSORS IN OLIGONUCLEOTIDE SYNTHESIS; USEFUL AS ANTISENSE INHIBITORS OF TRANSLATION | COMPETITIVE TECHNOLOGIES, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| US-5218103-A | Nucleoside thiophosphoramidites | UNIVERSITY PATENTS, INC. (US) | 1993-06-08 | — | — | US | disclosed |
| US-5118800-A | Oligonucleotides possessing a primary amino group in the terminal nucleotide | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1992-06-02 | — | — | US | disclosed |
| US-5015733-A | Phosphoramidites and oligonucleotides derived therefrom | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1991-05-14 | — | — | US | disclosed |
| WO-1991004983-A1 | NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES | UNIVERSITY PATENTS, INC. (US) | 1991-04-18 | — | — | WO | disclosed |
| US-4849513-A | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1989-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | NSUN2, POLL, DUT | ABL1 294/4885ABCB1 4379/4885BCR 1260/4885 |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | NSUN2, ADAR, POLL | ABL1 752/4885ABCB1 3708/4885BCR 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.